Study why some people with eczema get more severe
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at why disease tends to be more severe in some people with atopic dermatitis (eczema), especially those with a specific genetic change in the IL-4 receptor (IL-4Ra). The results may help explain what drives flare-ups and could guide better treatments in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 65 years old
- You must have atopic dermatitis (eczema) that meets standard diagnostic rules
- You cannot be enrolled in another clinical trial at the same time
- No immune-suppressing or immune-changing medicines in the last 4 weeks (like certain steroids, methotrexate, or JAK inhibitors)
- No eczema treatments right before the study that are specifically restricted (including bleach baths in the last 7 days, and certain skin creams in the last 7 days)
- You should not have certain infections or immune problems (like HIV/hepatitis/tuberculosis) or major medical illnesses that could affect safety
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether cleaning the skin to remove a common bacteria (Staph aureus) can help reduce eczema symptoms. It may offer a new way to manage eczema without relying only on creams or injections.
This study uses special imaging to look at the structure of skin, comparing people with eczema (who have used steroid creams) to healthy volunteers. Researchers want to understand how the skin changes with eczema and its treatment.
This observational study follows people with eczema (atopic dermatitis) and sometimes related allergies over time, even if they keep their usual medical treatments. It may help researchers better understand how these conditions change and what factors relate to symptoms.
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
This study looks at the types of germs on the skin (skin microbiome) in healthy people and people with skin conditions, including atopic dermatitis (eczema). Researchers collect skin samples to understand how skin germs differ and how that may relate to skin health.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.